OakChart

NewAmsterdam Pharma Company NV

NAMSHealthcare·Biotechnology·Netherlands·Mid·NASD·Nov 11 • 3:59 PM ET

20.72+1.54 (8.03%)
2026-11-11 22:00 CET
Market cap
2,300.26 USD m
Revenue, TTM
25.94 USD m
Net income, TTM
-204.89 USD m
Free cash flow, TTM
-150.86 USD m
EPS diluted, TTM
-1.71
P/E
-
Compare

Price

NAMS against its 20, 50 and 200-day averages
2050200beatmiss
20.0030.0040.002.4M4.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NAMSclose 20.7220-day 20.2150-day 21.75200-day 29.2720.7252w high52w low

50.9% under the 52-week high of 42.21 on 11 May 2026. 52-week low 17.90 on 9 Nov 2026. Last 15 sessions, 24.4% high to low

Volume 1.66× normal · the line is the 50-bar volume average

Profile

NAMS
52-week range, 12% of the way up
17.9042.21

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Employees100
IPOFeb 08, 2021
Beta0.15
ATR, 14d1.34
Rel volume1.66
Short float15.50%
Insider own35.41%
Inst own68.13%

Snapshot

6 groups

Valuation

Index-
Market Cap2.48B
Enterprise Value1.86B
Income-204.89M
Sales25.94M
Book/sh5.26
Cash/sh5.25
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees100
IPOFeb 08, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S95.80
P/B3.94
P/C3.95
P/FCF-
EV/EBITDA-
EV/Sales71.52
Quick Ratio11.76
Current Ratio11.76
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.71
EPS next Y-1.94
EPS next Q-0.45
EPS this Y10.39%
EPS next Y-26.10%
EPS next 5Y19.24%
EPS past 3/5Y-12.98% -
Sales past 3/5Y-39.71% -
EPS Y/Y TTM16.12%
Sales Y/Y TTM-26.41%
EPS Q/Q76.85%
Sales Q/Q5406.90%
EarningsNov 04 BMO
EPS/Sales Surpr.70.33% 117.28%

Ownership

Insider Own35.41%
Insider Trans-0.88%
Inst Own68.13%
Inst Trans-1.56%
ROA-27.79%
ROE-30.16%
ROIC-32.48%
Gross Margin99.05%
Oper. Margin-900.07%
Profit Margin-789.94%
SMA202.52%
SMA50-4.75%
SMA200-29.22%
Trades-

Technical

Shs Outstand119.82M
Shs Float77.46M
Short Float15.50%
Short Ratio7.69
Short Interest12.01M
52W High42.21 -50.91%
52W Low17.90 15.75%
Volatility8.32% 6.42%
ATR (14)1.34
RSI (14)50.31
Beta0.15
Rel Volume1.66
Avg Volume1.56M
Volume2,591,877

Performance

Perf Week-1.00%
Perf Month2.63%
Perf Quarter-22.31%
Perf Half Y-45.11%
Perf YTD-40.94%
Perf Year-48.06%
Perf 3Y107.41%
Perf 5Y111.00%
Perf 10Y-
Recom1.12
Target Price51.73
Prev Close19.18
Price20.72
Change %8.03%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Jul 21, 2026InitiatedBBMO Capital MarketsOutperform$58+179.9%
Mar 18, 2026InitiatedTTruistBuy$57+175.1%
Oct 20, 2025ResumedHH.C. WainwrightBuy$52+151.0%
Aug 25, 2025InitiatedWWells FargoOverweight$45+117.2%
Jul 17, 2025InitiatedGGoldmanNeutral$27+30.3%
Jun 17, 2025InitiatedCCitigroupBuy$42+102.7%
Jun 10, 2025InitiatedSStifelBuy$44+112.4%
Jun 04, 2025InitiatedCCantor FitzgeraldOverweight$42+102.7%
Dec 30, 2024InitiatedHH.C. WainwrightBuy$48+131.7%
May 15, 2024InitiatedTTD CowenBuy

Peers

Mkt cap
TickerCompanyMkt cap
ARWRArrowhead Pharmaceuticals Inc6.97B
IONSIonis Pharmaceuticals Inc4.72B
MLYSMineralys Therapeutics Inc1.43B
MRKMerck & Co Inc363.02B
AMGNAMGEN Inc253.07B
AZNAstrazeneca plc287.68B
SLNSilence Therapeutics Plc ADR1.23B
CRSPCRISPR Therapeutics AG4.49B
MDGLMadrigal Pharmaceuticals Inc10.06B
CYTKCytokinetics Inc8.15B

Insider trading

latest 14 of 59
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kastelein Johannes Jacob PieteChief Scientific OfficerSep 30 '26Sale25.0350,2461,257,65769,302Oct 02 04:30 PM
Davidson Michael H.Chief Executive OfficerSep 14 '26Buy22.6510,000226,500792,923Sep 15 04:30 PM
Smither John WDirectorSep 04 '26Sale25.321,60040,5128,760Sep 09 04:30 PM
Kastelein Johannes Jacob PieteChief Scientific OfficerAug 24 '26Sale26.91125,0003,363,75069,302Aug 25 04:30 PM
Kastelein Johannes Jacob PieteAffiliateAug 24 '26Proposed Sale27.87125,0003,483,750Aug 24 04:55 PM
Kooij Louise FrederikaChief Accounting OfficerJul 20 '26Option Exercise11.34105,0001,191,100129,353Jul 22 04:05 PM
Kooij Louise FrederikaChief Accounting OfficerJul 20 '26Sale30.34105,0003,185,65624,353Jul 22 04:05 PM
Kooij Louise FrederikaChief Accounting OfficerJun 22 '26Option Exercise11.2840,000451,00064,353Jun 24 04:10 PM
Kooij Louise FrederikaChief Accounting OfficerJun 22 '26Sale30.2040,0001,208,15924,353Jun 24 04:10 PM
Kooij Louise FrederikaChief Accounting OfficerMay 26 '26Option Exercise10.0765,000654,50089,353May 27 04:30 PM
Kooij Louise FrederikaChief Accounting OfficerMay 26 '26Sale35.6965,0002,319,85024,353May 27 04:30 PM
Louise KooijOfficerMay 26 '26Proposed Sale35.44210,0007,442,400May 26 05:04 PM
LANGE LOUIS GDirectorMar 11 '26Sale30.4244,6191,357,23010,360Mar 12 04:25 PM
Louis G. LangeAffiliateMar 11 '26Proposed Sale31.2744,6191,395,236Mar 11 04:08 PM

Held by

AUM
TickerCompanyAUM
CGMMCapital Group U.S. Small and Mid Cap ETFAUM: 3.67B
IBBiShares Biotechnology ETFAUM: 11.36B
VHTVanguard Health Care ETFAUM: 21.51B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
ESMLiShares ESG Aware MSCI USA Small-Cap ETFAUM: 2.76B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
FHLCFidelity MSCI Health Care Index ETFAUM: 4.12B
GURUGlobal X Guru Index ETFAUM: 57.42M
DRKYVistaShares Target 15 DRUKMacro Distribution ETFAUM: 18.17M
FMEDFidelity Disruptive Medicine ETFAUM: 30.30M

News

latest 14 of 200
  • NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results (GlobeNewswire) +5.18%
  • NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November (GlobeNewswire)
  • Group 1 Automotive and 4 More Stocks See Action From Activist Investors (Barrons.com)
  • NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease (GlobeNewswire)
  • Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) (PR Newswire)
  • NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) (GlobeNewswire)
  • Novartis Trial Failure Sparks Biopharma Options Frenzy (Schaeffer's Research)
  • Novartis's failed trial for cholesterol drug leads to broad biopharma selloff (MarketWatch)
  • NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
  • NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 (GlobeNewswire)
  • NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.140-0.472-0.14019.168.8216
2026Q22026-08-05-0.526-0.482-0.5203.722.8316
2026Q12026-05-07-0.402-0.459-0.3983.031.7415
2025Q42026-02-18-0.622-0.454-0.6550.042.8814
2025Q32025-11-05-0.608-0.391-0.6050.355.3114
2025Q22025-08-06-0.150-0.463-0.14719.133.4913
2025Q12025-05-08-0.346-0.492-0.3402.991.568
2024Q42025-02-26-0.916-0.486-0.95012.801.7610
2024Q32024-11-06-0.180-0.499-0.17629.111.879
2024Q22024-08-07-0.410-0.577-0.4122.281.218
2024Q12024-05-09-1.060-0.618-1.0611.401.627
2023Q42024-02-28-0.612-0.605-0.6550.981.916
2023Q32023-11-13-0.756-0.485-0.5642.992.974
2023Q22023-08-07-1.012-0.461-10.522.144
2023Q12023-05-08-0.425--2.03-4
2022Q42023-03-31-1.799-0.427-4.391.243

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-1.0430.179-1.193105.93104.94
2023FY-2.150-2.149-2.15414.0913.08
2024FY-2.497-2.031-2.56045.6433.77
2025FY-1.734-1.538-1.72022.5026.99
2026FY--1.541--40.04
2027FY--1.944--67.46
2028FY--0.906--302.55
2029FY-1.163--719.38
2030FY-3.164--1,106

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09151513.980.0040.00
2026Q4S2026-11-05151513.980.0040.00
2026Q4S2026-11-04151414.730.0040.00
2026Q4S2026-10-19150015.790.0040.00
2026Q4S2026-09-11151015.790.0040.00
2026Q4S2026-08-06151015.790.0040.00
2026Q4S2026-08-05151015.780.0040.00
2026Q4S2026-07-21150015.580.0040.00
2026Q4S2026-07-17151215.580.0040.00
2026Q4S2026-06-29141216.260.0040.00
2026Q4S2026-05-07141216.270.0040.00
2026Q4S2026-05-04130015.940.0040.00
2026Q4S2026-05-03132115.940.0040.00
2026Q4S2026-03-17133115.940.0040.00

Estimate history

EPS, annual0.002-1.401-1.193-2.154-2.56-1.721-1.7128
Period202020212022202320242025TTM
EPS, quarterly-0.176-0.95-0.34-0.147-0.605-0.655-0.398-0.52-0.14
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00102.69414.0945.56322.50325.94
Period202020212022202320242025TTM
Sales, quarterly29.11112.7722.97819.1450.3480.0323.043.70119.164
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.75111.32581.5682.47108.064114.399119.819
Period202020212022202320242025MRQ
Shares, quarterly92.166108.064112.169112.51113.173114.399116.642117.652119.819
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue25.9422.5045.5614.09102.690.000.00
Cost of Goods Sold Incl. D&A0.250.220.110.050.010.020.00
Gross Profit25.6922.2845.4514.04102.69-0.020.00
Selling, General and Administrative Excl. Other259.14247.97221.74194.84104.0034.340.13
Research and Development157.63141.83151.41159.4286.7429.59-
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-233.45-225.68-176.29-180.80-1.32-34.35-0.13
Interest Expense----0.290.26-
Unusual Expense-9.1718.7875.5912.4511.280.91-0.62
Net Income Before Taxes-203.68-203.82-241.60-176.91-22.63-33.800.04
Income Taxes1.210.00-0.000.030.000.000.00
Consolidated Net Income-204.89-203.82-241.60-176.94-22.63-33.800.04
Net Income From Continuing Operations-204.89-203.82-241.60-176.94-22.63-33.800.04
Net Income-204.89-203.82-241.60-176.94-22.63-33.800.04
EPS (Recurring)-1.70-1.61-2.00-2.05-0.78-1.37-0.02
EPS (Basic, Before Extraordinaries)-1.71-1.72-2.56-2.15-1.19-1.400.00
EPS (Diluted)-1.71-1.72-2.56-2.15-1.19-1.400.00
EBITDA-233.21-225.46-176.18-180.75-1.31-34.34-0.13
Non-Operating Income (Expense)20.6040.6510.2816.34-9.751.72-0.45
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense49.0444.099.416.141.031.24-
Price To Earnings Ratio-----41.4252.54
Price To Sales Ratio116.40184.6153.2265.132.01--
Gross Margin99.0599.0299.7599.6599.99--
Operating Margin-900.07-1,002.90-386.91-1,283.17-1.28--
Net Margin-789.94-905.74-530.25-1,255.76-22.04--
Shares Outstanding119.82114.40108.0682.4781.5611.3317.75
Market Capitalization2,300.262,300.262,745.61919.56193.49173.07172.89

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue19.163.703.040.030.3519.142.9812.77
Cost of Goods Sold Incl. D&A0.070.060.060.060.060.040.050.05
Gross Profit19.103.642.98-0.030.2819.102.9312.72
Selling, General and Administrative Excl. Other63.2868.5161.4065.9555.4354.7371.8555.95
Research and Development39.3641.6738.0138.5930.9727.5244.7534.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-44.19-64.86-58.42-65.98-55.14-35.63-68.92-43.23
Unusual Expense-23.124.55-5.9415.3423.79-2.59-17.7545.56
Net Income Before Taxes-16.18-64.14-48.44-74.92-72.00-17.36-39.53-92.18
Income Taxes1.210.000.000.000.000.000.000.00
Consolidated Net Income-17.39-64.14-48.44-74.92-72.00-17.36-39.53-92.18
Net Income From Continuing Operations-17.39-64.14-48.44-74.92-72.00-17.36-39.53-92.18
Net Income-17.39-64.14-48.44-74.92-72.00-17.36-39.53-92.18
EPS (Recurring)-0.27-0.49-0.43-0.56-0.47-0.16-0.45-0.62
EPS (Basic, Before Extraordinaries)-0.14-0.52-0.40-0.65-0.61-0.15-0.34-0.95
EPS (Diluted)-0.14-0.52-0.40-0.65-0.61-0.15-0.34-0.95
EBITDA-44.12-64.81-58.36-65.92-55.08-35.59-68.87-43.18
Non-Operating Income (Expense)4.895.284.046.396.9315.6811.64-3.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.8914.5214.2210.4111.1411.264.262.64
Price To Sales Ratio116.40587.14172.66178.3496.0333.5450.4354.73
Gross Margin99.6598.4197.96-84.3881.6199.7698.2599.60
Operating Margin-230.58-1,752.61-1,921.71-206,187.50-15,845.69-186.13-2,314.47-338.47
Net Margin-90.74-1,732.91-1,593.45-234,134.38-20,691.09-90.70-1,327.30-721.71
Shares Outstanding119.82117.65116.64114.40113.17112.51112.17108.06
Market Capitalization2,300.263,961.883,680.353,977.763,203.142,033.232,247.972,745.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments637.56834.19340.45467.7360.381.37
Short Term Receivables23.1521.301.882.074.880.00
Inventories0.000.000.000.000.000.00
Other Current Assets14.997.924.468.181.700.50
Total Current Assets675.70863.41346.79477.9866.951.87
Net Property, Plant & Equipment0.570.670.100.150.220.00
Total Investments and Advances92.610.000.000.000.00138.00
Long-Term Note Receivable---0.000.82-
Intangible Assets0.410.530.170.210.000.00
Other Assets0.000.000.040.160.000.00
Total Assets769.28864.62347.10478.5067.98139.87
Short Term Debt Incl. Current Port. of LT Debt0.140.250.060.070.060.00
Accounts Payable8.974.7416.9211.857.070.16
Other Current Liabilities76.68101.9332.9124.144.100.07
Total Current Liabilities85.79106.9249.9036.0611.240.24
Long Term Debt0.070.200.000.060.130.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.008.8112.310.0012.17
Total Liabilities85.85107.1258.7048.4311.3612.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity683.43757.50288.39430.0756.62127.46
Total Shareholders Equity683.43757.50288.39430.0756.62127.46
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity683.43757.50288.39430.0756.62127.46
Total Liabilities & Stockholders Equity769.28864.62347.10478.5067.98139.87
Book Value Per Share5.977.013.505.275.007.18
Tangible Book Value Per Share5.977.003.495.275.007.18
Full-Time Employees10068291744
Price to Book Ratio3.646.251.991.521.311.32
Return on Assets-24.95-39.88-38.70-7.32-49.72-
Return on Equity-28.29-46.20-43.93-8.06-59.70-
Return on Invested Capital-29.82-31.89-61.35-5.26-59.570.03
Quick Ratio7.888.086.9513.265.967.90
Current Ratio7.888.086.9513.265.967.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-204.89-203.82-241.60-176.94-22.63-33.800.04
Depreciation0.250.220.110.050.010.02-
Other Funds (Non Cash)56.2263.76115.5929.8022.92-0.47-0.13
Funds from Operations-148.42-139.84-125.89-147.080.29-34.26-0.08
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-2.04-7.94-32.675.8710.374.52-0.42
Cash from Operating Activities-150.47-147.78-158.56-141.2210.66-29.74-0.50
Capital Expenditures-0.40-0.25-0.67-0.02-0.22-0.020.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-3.32-174.670.000.000.000.000.00
Purchase of Investments-198.21-296.730.000.000.000.000.00
Sale Or Maturity of Investments194.89122.060.000.000.000.000.00
Other Uses0.000.00-62.180.000.000.00-138.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-3.71-174.92-62.85-0.02-0.22-0.02-138.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock41.2429.52660.508.91391.1681.56139.95
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock41.2429.52660.508.91391.1681.56139.95
Proceedsfrom Stock Options0.00-1.59-0.540.00391.1681.56139.95
Issuance or Reduction of Debt, Net0.000.000.000.000.75-0.010.00
Change in Long Term Debt0.000.000.00--0.000.00
Issuance of Long Term Debt0.000.000.00--0.000.00
Reduction of Long Term Debt0.000.000.00--0.000.00
Net Financing Active Other Cash Flow0.000.00-0.990.000.000.00-0.08
Other Financing Activities Uses0.000.00-0.990.000.000.00-0.08
Cash from Financing Activities41.2429.52659.518.91391.9081.54139.87
Exchange Rate Effect-2.1512.76-6.805.055.251.68-
Net Change in Cash-115.09-280.42431.29-127.28407.6053.461.37
Free Cash Flow-150.86-148.03-159.24-141.2410.44-29.77-0.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Price to Free Cash Flow----19.79--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments629.74635.21637.44637.56704.25739.16
Short Term Receivables27.005.348.2223.1520.2519.75
Inventories0.000.000.000.000.000.00
Other Current Assets15.4318.6512.3814.997.8310.94
Total Current Assets672.16659.21658.04675.70732.33769.85
Net Property, Plant & Equipment0.630.490.400.570.570.62
Total Investments and Advances14.8844.4171.2492.6153.0944.17
Intangible Assets0.310.340.380.410.440.47
Other Assets0.000.002.580.000.000.00
Total Assets687.99704.45732.64769.28786.43815.11
Short Term Debt Incl. Current Port. of LT Debt0.030.030.020.140.180.23
Accounts Payable4.635.428.098.973.635.89
Other Current Liabilities52.5067.5359.3176.6854.4630.39
Total Current Liabilities57.1572.9767.4285.7958.2736.51
Long Term Debt0.050.060.000.070.090.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities57.2073.0367.4285.8558.3636.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity630.78631.42665.22683.43728.07778.50
Total Shareholders Equity630.78631.42665.22683.43728.07778.50
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity630.78631.42665.22683.43728.07778.50
Total Liabilities & Stockholders Equity687.99704.45732.64769.28786.43815.11
Book Value Per Share5.265.375.705.976.436.92
Tangible Book Value Per Share5.265.365.705.976.436.92
Full-Time Employees---100--
Price to Book Ratio3.645.945.365.454.112.61
Return on Assets-27.79-34.16-27.43-24.95-36.08-26.27
Return on Equity-30.16-36.81-29.49-28.29-39.94-28.43
Return on Invested Capital-2.76-10.16-7.28-10.96-9.89-2.23
Quick Ratio11.769.039.767.8812.5721.08
Current Ratio11.769.039.767.8812.5721.08

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-17.39-64.14-48.44-74.92-72.00-17.36
Depreciation0.070.060.060.060.060.04
Other Funds (Non Cash)-10.3023.4213.6829.4238.193.49
Funds from Operations-27.62-40.66-34.70-45.44-33.75-13.83
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-12.151.444.104.570.98-23.84
Cash from Operating Activities-39.77-39.21-30.60-40.88-32.77-37.67
Capital Expenditures-0.18-0.08-0.04-0.10-0.04-0.09
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments33.88-4.68-11.47-21.042.55-156.18
Purchase of Investments-13.01-51.18-62.47-71.54-31.85-193.34
Sale Or Maturity of Investments46.8946.5051.0050.5034.4037.16
Other Uses0.000.000.000.000.009.63
Other Sources0.000.000.000.000.00-12.50
Cash from Investing Activities33.70-4.76-11.51-21.142.51-159.14
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.4511.0411.0613.685.893.42
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.4511.0411.0613.685.893.42
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.4511.0411.0613.685.893.42
Exchange Rate Effect-0.26-0.50-1.33-0.060.228.83
Net Change in Cash-0.88-33.44-32.38-48.39-24.15-184.56
Free Cash Flow-39.95-39.29-30.64-40.98-32.81-37.76

Revenue breakdown

Pharmaceutical Preparations2024: 45.56M 2025: 22.50M
Netherlands2024: 45.56M 2025: 22.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.50%12.0M77.5M1.46M
2026-10-1518.27%14.1M77.2M1.39M
2026-09-3024.97%19.0M76.3M1.31M
2026-09-1520.30%15.7M77.1M1.18M
2026-08-3117.32%13.4M77.3M1.13M
2026-08-1416.37%12.7M77.3M1.18M
2026-07-3112.09%10.0M82.4M1.30M
2026-07-1511.46%9.2M80.1M1.28M
2026-06-3011.35%9.1M80.1M1.29M
2026-06-1511.46%9.2M80.1M1.20M
2026-05-297.63%8.1M106.2M1.16M
2026-05-158.90%7.1M80.2M1.08M
2026-04-3010.62%7.9M74.2M855.55K
2026-04-1510.38%7.7M74.0M791.13K
2026-03-3111.17%8.0M72.0M789.57K
2026-03-1310.47%7.5M72.0M781.01K
2026-02-2710.63%7.7M72.0M802.68K
2026-02-139.65%7.0M72.0M845.87K
2026-01-308.84%7.1M80.4M901.69K
2026-01-157.86%6.3M80.4M1.00M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5016.2020.200.0022.4250.000.000.995-0.0180.000
call5.0013.7017.700.0012.2440.000.000.956-0.2160.003
call7.5011.2015.300.008.9840.000.000.923-0.2410.005
call10.008.7012.800.006.8290.000.000.888-0.2420.006
call12.506.2010.100.005.1770.000.000.846-0.2320.008
call15.003.707.800.004.0080.000.000.795-0.2170.009
call17.501.304.900.002.5380.000.000.723-0.2000.011
call20.000.002.000.601.2705010.000.607-0.1380.012
call22.500.100.650.650.9892932.000.362-0.0790.012
call25.000.000.250.121.0774860.000.150-0.0460.008
call30.000.000.250.101.8471,1330.000.102-0.0570.006
call35.000.000.250.202.3192800.000.086-0.0630.005
call40.000.000.053.822.0685.000.000.023-0.0180.002
call45.000.002.154.092.35913.000.000.021-0.0200.002
call50.000.002.151.852.6000.000.000.019-0.0210.001
call55.000.002.150.002.8130.000.000.018-0.0210.001
call60.000.002.150.003.0040.000.000.017-0.0220.001
put2.500.000.050.006.1420.000.00-0.006-0.0160.001
put5.000.002.150.0012.4600.000.00-0.047-0.2060.003
put7.500.002.150.009.1240.000.00-0.077-0.2390.005
put10.000.002.150.006.6630.000.00-0.121-0.2280.006
put12.500.002.150.005.0790.000.00-0.167-0.2160.008
put15.000.002.200.003.8550.000.00-0.227-0.1970.009
put17.500.002.400.483.2358.000.00-0.279-0.1970.011
put20.000.002.501.502.25914.000.00-0.395-0.1350.012
put22.500.354.303.002.5175.000.00-0.646-0.0740.012
put25.004.106.306.002.7101540.00-0.850-0.0430.008
put30.007.6011.305.903.5650.000.00-0.895-0.0530.006
put35.0012.6016.300.004.2050.000.00-0.913-0.0590.005
put40.0017.6021.300.004.7170.000.00-0.977-0.0150.002
put45.0022.5026.300.005.1450.000.00-0.979-0.0150.002
put50.0027.5031.300.005.5120.000.00-0.981-0.0160.002
put55.0032.5036.300.005.8330.000.00-0.982-0.0160.001
put60.0037.5041.300.006.1180.000.00-0.983-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-22SCHEDULE 13D/ASEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-25144/ASEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-148-K/A2026-07-16SEC
2026-08-143Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-148-KCurrent report2026-08-10SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-228-KCurrent report2026-07-16SEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-04SCHEDULE 13G/ASEC
2026-06-038-KCurrent report2026-06-02SEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-26144Filing for proposed sale of securities under Rule 144.SEC
2026-05-14SCHEDULE 13D/ASEC
2026-05-078-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09226.50K11.30M2
2026-08003.36M1
2026-07003.19M1
2026-06001.21M1
2026-05002.32M1
2026-040000
2026-030026.03M6
2026-020012.18M4
2026-01008.47M9
2025-12005.20M3
2025-110000

Institutional holders

Manager% owned
Frazier Life Sciences Management, L.P.15.47%
Capital World Investors10.46%
FMR LLC10.14%
RA CAPITAL MANAGEMENT, L.P.8.17%
FCPM III SERVICES B.V.7.26%
DEERFIELD MANAGEMENT COMPANY, L.P.3.65%
VIKING GLOBAL INVESTORS LP3.60%
Bain Capital Life Sciences Investors, LLC3.26%
MAVERICK CAPITAL LTD2.80%
Duquesne Family Office LLC2.63%

Funds

Fund% owned
SMALLCAP World Fund Inc7.93%
VANGUARD HEALTH CARE FUND2.93%
Strategic Advisers Fidelity U.S. Total Stock Fund1.92%
Fidelity Contrafund1.44%
Select Health Care Portfolio0.82%
New Economy Fund0.80%
T. Rowe Price Health Sciences Fund, Inc.0.78%
Capital Group U.S. Small and Mid Cap ETF0.59%
iShares Biotechnology ETF0.48%
Small Cap Growth Fund0.45%

OakChart. NAMS. Cached 15 minutes.